News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rainbow BioSciences, LLC: Alzheimer's Epidemic Draws $100 Million in Research


10/24/2012 9:00:53 AM

NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp.’s (OTCBB:RBCC) biotech subsidiary, Rainbow BioSciences, nears a deal with Amarantus BioSciences (OTCBB: AMBS), the Alzheimer’s epidemic is already drawing $100 million worth of disease research from big drug companies. A $100 million drug trial will begin next year in the isolated villages of Antioquia, Columbia, where a genetic mutation in the community’s blood line has led to a higher concentration of Alzheimer’s sufferers than anywhere else in the world. About 5,000 residents of the area now form the biggest and best pool of potential Alzheimer’s patients anywhere—a solid trial group for drug companies working on a cure. “This massive research expenditure in Columbia just goes to show how desperate the world is for a cure to this disease,” said RBCC CEO Patrick Brown. “There is a huge a market developing around the globe for effective new Alzheimer’s treatments, and we’re working very hard to capitalize on that demand.”

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES